Dividends Inside 
Merck & Co., Inc.
MRK
$129.56 (+ $4.19 + 3.34%)
Last updated: 2026-07-04 03:36 UTC
Merck & Co., Inc. trades under ticker MRK on NYSE as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US58933Y1055, CUSIP 58933Y105.
About the Company
Merck & Co., Inc. operates as a leading healthcare company worldwide, specializing in the research, development, and commercialization of innovative pharmaceutical products and vaccines. Its portfolio features prominent human health pharmaceuticals such as Keytruda for oncology treatments, Welireg for specific cancer therapies, and Gardasil for HPV prevention. The company also provides a robust lineup of vaccines including ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, and Pneumovax 23, addressing infectious diseases across age groups. Additional offerings include Bridion for surgical care. Merck & Co., Inc. focuses on key therapeutic areas like oncology, vaccines, hospital acute care, and immunology, serving patients, healthcare providers, and global health systems. Through its operations, the company plays a vital role in advancing treatments for serious diseases and preventive health measures. Founded in 1891 and headquartered in Rahway, New Jersey, Merck & Co., Inc. maintains a strong presence in the biopharmaceutical sector, contributing to global health solutions.
Price History
Latest News for MRK
Merck to buy oncology firm Terns Pharmaceuticals in $6.7 billion deal
Investing.com -- Pharmaceutical giant Merck announced Wednesday that it will acquire clinical-stage oncology company Terns Pharmaceuticals for $53.00 per share in cash, representing an approximate equity value of $6.7 billion. The deal equates to approximately $5.7 billion net of acquired cash and represents a premium of 31% to the 60-day and 42% to the 90-day volume-weighted average stock price on Tuesday.
Citi Raises its Price Target on Merck & Co. (MRK) to $125 from $120
Merck & Co., Inc. (NYSE:MRK) is one of the 10 Most Profitable S&P 500 Stocks to Buy Now. On March 20, 2026, Citi raised the price target on Merck & Co., Inc. (NYSE:MRK) to $125 from $120 and maintained a Neutral rating. On March 18, 2026, Merck’s Animal Health division announced that the FDA approved […]
MSD and Quotient collaborate on IBD drug targets
The somatic genomics approach analyses naturally accumulated genetic mutations within individual patient tissue.
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for certain patients with CML Merck to hold investor call at 8 a.m. EDT today RAHWAY, N.J. and FOSTER CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that the companies have ent
Update: Market Chatter: Merck Nears $6 Billion Deal to Acquire Terns Pharma
(Updates with Terns ticker symbol in the first paragraph and latest stock move in the fifth paragrap
Assessing Merck (MRK) Valuation After New IBD Genetics Collaboration With Quotient Therapeutics
Why Merck’s new IBD genetics deal matters for MRK stock Merck (MRK) just signed a multi year research collaboration with Quotient Therapeutics focused on inflammatory bowel disease, built around Quotient’s somatic genomics platform and a milestone structure worth up to US$2.2b. Quotient receives an upfront US$20 million payment, while Merck gains access to a technology that examines naturally occurring somatic mutations in patient tissues to identify targets that may drive or protect against...